Vabomere
Total Payments
$1.5M
Transactions
8,551
Doctors
3,501
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $94,682 | 84 | 53 |
| 2023 | $265,082 | 709 | 460 |
| 2022 | $185,034 | 1,327 | 759 |
| 2021 | $55,541 | 903 | 564 |
| 2020 | $207,964 | 537 | 323 |
| 2019 | $274,534 | 2,185 | 1,094 |
| 2018 | $416,287 | 2,806 | 1,378 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $591,364 | 127 | 39.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $481,963 | 245 | 32.1% |
| Food and Beverage | $208,893 | 7,502 | 13.9% |
| Consulting Fee | $121,895 | 19 | 8.1% |
| Travel and Lodging | $78,794 | 337 | 5.3% |
| Education | $16,216 | 321 | 1.1% |
Payments by Type
General
$907,760
8,424 transactions
Research
$591,364
127 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An Open label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of a Single Dose Infusion of VABOMERE (meropenem-vaborbactam) in Pediatric Subjects from Birth to Less Than 18 Years of Age with Serious Bacterial Infections | Melinta Therapeutics, LLC | $144,296 | 1 |
| An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of a Single Dose Infusion of VABOMERE (Meropenem-Vaborbactam) in Pediatric Subjects From Birth to Less Than 18 Years of Age With Serious Bacterial Infections | Melinta Therapeutics, LLC | $103,900 | 0 |
| Stability of Meropenem and Vaborbactam at Room and Refigerated Temperatures in PCV IV infusion bags and Elastomeric Devices | Melinta Therapeutics, Inc. | $62,842 | 0 |
| Clinical and Economic Implications to the Hospital of Failure to Update Microbiology Breakpoints for Carbapenem-Resistant Enterobacteriaceae | Melinta Therapeutics, LLC | $58,840 | 0 |
| Rempex 507 | Melinta Therapeutics, Inc. | $42,544 | 1 |
| Stability of Meropenem and Vaborbactam at Room and Refrigerated Temperatures in PVC IV Infusion Bags and Elastomeric Devices | Melinta Therapeutics, LLC | $36,221 | 0 |
| REMPEX 512 | Melinta Therapeutics, Inc. | $26,711 | 0 |
| A retrospective comparative cohort study evaluating multidrug resistant bacterial infections (MDRO) and outcomes with meropenem/vaborbactam | Melinta Therapeutics, LLC | $26,666 | 0 |
| A retrospective comparative cohort study evaluating multidrug resistantbacterial infections (MDRO) and outcomes with meropenem/vaborbactam | Melinta Therapeutics, Inc. | $13,334 | 0 |
| Susceptibility to meropenem-vaborbactam and comparator agents in relation to clonal background among international carbapenem-resistant Escherichia coli clinical isolates | Melinta Therapeutics, LLC | $12,053 | 0 |
| Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections | Melinta Therapeutics, LLC | $11,360 | 0 |
| Meropenem/vaborbactam versus ceftazidime/avibactam for treatment of carbapenem-resistant Enterobacteriaceae infections | Melinta Therapeutics, Inc. | $11,360 | 0 |
| REMPEX-507 | Melinta Therapeutics, Inc. | $11,002 | 0 |
| Impact of Extracorporeal Membrane Oxygenation Circuitry on Meropenem/Vaborbactam | Melinta Therapeutics, LLC | $9,868 | 0 |
| In Vitro Activity of New Drug against Chlamydia Pneumoniae | Melinta Therapeutics, Inc. | $9,866 | 0 |
| Rempex 510 complicated urinary tract infections (cUTIs) study | Melinta Therapeutics, LLC | $5,550 | 1 |
| DEL 201 antibacterial study | Melinta Therapeutics, LLC | $4,950 | 1 |
Top Doctors Receiving Payments for Vabomere
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Charolotte, NC | $505,259 | 124 |
| , M.D | Anesthesiology | Lexington, MA | $153,000 | 18 |
| , M.D | Infectious Disease | Sylmar, CA | $43,982 | 76 |
| , M.D | Pulmonary Disease | Goshen, MA | $41,500 | 1 |
| , DPM | Podiatrist | Highland Park, IL | $39,579 | 105 |
| , M.D | Internal Medicine | Madison, NJ | $34,712 | 53 |
| , M.D | Critical Care Medicine | Augusta, GA | $30,920 | 34 |
| , MD | Infectious Disease | Carmel, IN | $25,584 | 25 |
| , M.D | Internal Medicine | Edinburg, TX | $24,178 | 34 |
| , D.O | Infectious Disease | Lake Mary, FL | $23,168 | 50 |
| , MD, PHARMD | Student in an Organized Health Care Education/Training Program | Pittsburgh, PA | $21,908 | 33 |
| , MD | Infectious Disease | Lake Mary, FL | $21,816 | 55 |
| , DO | Infectious Disease | Orlando, FL | $21,634 | 42 |
| , M.D | Infectious Disease | Shreveport, LA | $21,024 | 35 |
| , M.D | Infectious Disease | Brookline, MA | $20,670 | 25 |
| , MD | Internal Medicine | Sacramento, CA | $19,768 | 27 |
| , M.D | Infectious Disease | Beeville, TX | $17,288 | 30 |
| , MD | Infectious Disease | Memphis, TN | $16,648 | 23 |
| , M.D | Infectious Disease | Fort Wayne, IN | $15,860 | 28 |
| , M.D | Infectious Disease | Manhasset, NY | $14,830 | 22 |
| , M.D | Internal Medicine | Chicago, IL | $13,809 | 35 |
| , M.D | Infectious Disease | Morgantown, WV | $12,383 | 20 |
| , MD | Infectious Disease | San Diego, CA | $11,926 | 32 |
| , M.D | Infectious Disease | Murrieta, CA | $10,911 | 17 |
| , MD | Infectious Disease | Huntsville, AL | $9,936 | 36 |
Ad
Manufacturing Companies
- Melinta Therapeutics, LLC $808,303
- Melinta Therapeutics, Inc. $690,821
Product Information
- Type Drug
- Total Payments $1.5M
- Total Doctors 3,501
- Transactions 8,551
About Vabomere
Vabomere is a drug associated with $1.5M in payments to 3,501 healthcare providers, recorded across 8,551 transactions in the CMS Open Payments database. The primary manufacturer is Melinta Therapeutics, Inc..
Payment data is available from 2018 to 2024. In 2024, $94,682 was paid across 84 transactions to 53 doctors.
The most common payment nature for Vabomere is "Unspecified" ($591,364, 39.4% of total).
Vabomere is associated with 17 research studies, including "An Open label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of a Single Dose Infusion of VABOMERE (meropenem-vaborbactam) in Pediatric Subjects from Birth to Less Than 18 Years of Age with Serious Bacterial Infections" ($144,296).